CEL-SCI receives approval to expand Phase III trial to U.K. CEL-SCI Corporation announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted regulatory approval to begin the company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine in the United Kingdom. The U.K. becomes the 13th country to join the trial. Several hospitals and medical clinics in the UK are expected to participate in the Phase III trial for the treatment of head and neck cancer. Further expansion of the trial is underway with a goal to have a total of about 100 clinical centers through 20 countries by the end of 2015. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care vs. subjects who are treated with SOC only.